A Francisella tularensis Live Vaccine Strain That Improves Stimulation of Antigen-Presenting Cells Does Not Enhance Vaccine Efficacy by Schmitt, Deanna M. et al.
A Francisella tularensis Live Vaccine Strain That Improves
Stimulation of Antigen-Presenting Cells Does Not
Enhance Vaccine Efficacy
Deanna M. Schmitt
1, Dawn M. O’Dee
1, Joseph Horzempa
1,2, Paul E. Carlson Jr.
1¤, Brian C. Russo
1,
Jacqueline M. Bales
1, Matthew J. Brown
1, Gerard J. Nau
1,3,4*
1Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America, 2Department of
Natural Sciences and Mathematics, West Liberty University, West Liberty, West Virginia, United States of America, 3Department of Medicine – Division of Infectious
Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America, 4Center for Vaccine Research, University of Pittsburgh School of
Medicine, Pittsburgh, Pennsylvania, United States of America
Abstract
Vaccination is a proven strategy to mitigate morbidity and mortality of infectious diseases. The methodology of identifying
and testing new vaccine candidates could be improved with rational design and in vitro testing prior to animal
experimentation. The tularemia vaccine, Francisella tularensis live vaccine strain (LVS), does not elicit complete protection
against lethal challenge with a virulent type A Francisella strain. One factor that may contribute to this poor performance is
limited stimulation of antigen-presenting cells. In this study, we examined whether the interaction of genetically modified
LVS strains with human antigen-presenting cells correlated with effectiveness as tularemia vaccine candidates. Human
dendritic cells infected with wild-type LVS secrete low levels of proinflammatory cytokines, fail to upregulate costimulatory
molecules, and activate human T cells poorly in vitro. One LVS mutant, strain 13B47, stimulated higher levels of
proinflammatory cytokines from dendritic cells and macrophages and increased costimulatory molecule expression on
dendritic cells compared to wild type. Additionally, 13B47-infected dendritic cells activated T cells more efficiently than LVS-
infected cells. A deletion allele of the same gene in LVS displayed similar in vitro characteristics, but vaccination with this
strain did not improve survival after challenge with a virulent Francisella strain. In vivo, this mutant was attenuated for
growth and did not stimulate T cell responses in the lung comparable to wild type. Therefore, stimulation of antigen-
presenting cells in vitro was improved by genetic modification of LVS, but did not correlate with efficacy against challenge
in vivo within this model system.
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Introduction
The development of vaccines is essential to combat harmful
infectious diseases [1]. Obtaining licensure after discovery of a
vaccine, however, can take up to 20 years due to the stringent
testing required to confirm the safety and efficacy of the vaccine
[2]. To expedite this process, in vitro tests could be developed to
define correlates of protection and identify more promising
vaccine candidates. These assays would be particularly beneficial
with vaccine candidates for highly pathogenic organisms, such as
the bacterium Francisella tularensis, when challenge studies cannot
be performed in humans because of contemporary regulations that
govern clinical trials [3].
F. tularensis is the causative agent of tularemia [4]. This zoonotic
disease is endemic in North America and parts of Europe and
Asia, and outbreaks in these regions are frequently associated with
the handling of infected animals or transmission by arthropod
vectors [4,5]. F. tularensis is also classified by the Centers for
Disease Control and Prevention as a Category A bioterrorism
agent [6]. When inhaled, less than 10 organisms can cause an
acute pneumonia that is lethal in up to 60% of infected individuals
if left untreated [7]. The World Health Organization predicted
that if virulent F. tularensis was aerosolized over a metropolitan area
of five million people, more than 19,000 people would die and
250,000 individuals would be incapacitated [6]. An effective
vaccine would be useful to reduce the number of naturally
occurring tularemia cases and to protect against a possible
intentional release.
To date, two different types of tularemia vaccines have been
studied in humans. The Foshay vaccine consisted of chemically
killed F. tularensis and was effective at reducing the incidence of
laboratory-acquired tularemia cases from approximately 100% to
30% in the 1950s [8,9]. However, killed F. tularensis provided only
minimal protection from aerosol type A Francisella challenge in a
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different approach and developed a range of live attenuated
Francisella strains to immunize people against tularemia [11]. One
of these strains, a live attenuated strain of F. tularensis subsp. holarctica,
live vaccine strain (LVS), was superior to the Foshay-type vaccines at
providing protection [10,12,13]. While two clinical studies involving
small numbers of human vaccinees demonstrated effectiveness of
LVSagainstaerosol challengebyvirulent typeA Francisella[10,12],a
later study showed variable efficacy that diminished over time [14].
Vaccination of individuals by aerosol improved the efficacy of LVS
but this required a high dose of 10
6 to 10
8 organisms which
frequently resulted in severe adverse side effects [14].
Currently, LVS is not approved by the Food and Drug
Administration (FDA) due to concerns about its undefined
attenuation, mechanism of protection, and reversion frequency
[15]. In order to obtain FDA approval, several groups are working
to address these issues. Recent work by Salomonsson et al. identified
two regions of difference, RD18 and RD19, which are deleted in
LVS and account for its attenuation [16]. Additional studies
improved the manufacturing process of LVS in compliance with
good manufacturing practice guidelines [17]. This new lot of LVS
was further characterized in human phase I clinical trials [18].
Researchers are also introducing mutations into LVS in order to
improve itsefficacyandbolster attenuation.Oneexample isanLVS
mutant deficient in iron superoxide dismutase (sodBFt). Compared to
LVS, sodBFt increases median time to death and percent survival of
C57BL/6micefrom pulmonarytypeA Francisella challenge [19].As
work toward the licensing of LVS continues, attempts have been
made to replace LVS with a genetically defined, attenuated type A
Francisella strain. For example, Schu S4 DFTT_1103 and Schu S4
DclpB, provide 75% and 60% protection, respectively, from virulent
type A Francisella challenge in BALB/c mice [20,21]. Nevertheless,
LVS remains the leading tularemia vaccine to date that has shown
activity in humans [10,12].
A potential limitation of LVS as a vaccine is its relative
stimulation of antigen-presenting cells (APCs). Published work has
shown LVS stimulates murine and human DCs [22,23], though it
is now known that culture conditions influence stimulation of
innate immunity [24,25,26,27,28]. In contrast, other studies have
shown that LVS suppresses the activation of murine macrophages
[24,29,30,31,32] and dendritic cells (DCs) [32]. Murine macro-
phages and DCs cultured with LVS produce little to no
proinflammatory cytokines in vitro compared to DCs cultured with
other bacteria or TLR ligands [24,29,30,32]. Stimulation with
TLR ligands such as Escherichia coli LPS fails to restore cytokine
secretion by these cells suggesting that LVS is actively suppressing
TLR signaling [24,25,29,32]. Another study showed that this
suppression is due to downregulation of critical inflammatory
signaling pathways involved in MAPK and NF-kB activation [30].
In this study, we tested whether in vitro screening of potential
tularemia vaccine candidates for enhanced stimulation of APCs
would improve a candidate’s immunogenicity, and ultimately
protection after challenge. After initial testing of several LVS
strains, we evaluated one genetic locus in detail with mutant strains
that showed desirable vaccine characteristics in vitro, including
attenuation in macrophages and enhanced DC stimulation.
Despite these traits, they did not predict better protection against
virulent type A Francisella challenge.
Materials and Methods
Ethics Statement
Human cells were purified from discarded buffy coats obtained
from the Central Blood Bank (Pittsburgh, PA). The use of these
samples was reviewed and approved by the Institutional Review
Board of the University of Pittsburgh, which made a ‘‘no human
subjects’’ determination and waived requirement for consent. All
research involving animals was conducted in accordance with
animal care and use guidelines, and animal protocols were
approved by the University of Pittsburgh Animal Care and Use
Committee (protocols 1003587 and 1002514).
Francisella strains and growth conditions
For cultivation of F. tularensis LVS strains and Schu S4, frozen
stock cultures were streaked onto chocolate II agar plates and
incubated at 37uC, 5% CO2 for 2–3 days. LVS strains were grown
in Chamberlain’s chemically defined broth medium (CDM) [33]
or MH broth [Mueller-Hinton broth (Difco) supplemented with
0.1% glucose, 0.025% ferric pyrophosphate (Sigma), and Iso-
VitaleX (Becton Dickinson)] for in vitro infections. For mouse
vaccinations, MH broth or TSBc [trypticase soy broth (BD
Biosciences) supplemented with 0.1% L-cysteine hydrochloride
monohydrate (Fisher)] was used for culturing of LVS strains. Schu
S4 was grown in MH broth for infections of vaccinated mice.
Broth cultures were grown at 37uC with shaking for 14–18 hours.
When required, antibiotics were added to the media at the
following concentrations: kanamycin at 10 mg/ml, chloramphen-
icol at 5 mg/ml, and hygromycin at 200 mg/ml.
Generation of formalin-fixed Francisella tularensis Schu S4
(ffSchu S4)
Schu S4 was grown in MH broth as described above. Following
overnight culture, bacteria were washed, resuspended in PBS
(Gibco), and adjusted to an OD600 of 0.3. Bacteria were then
resuspended in 10% buffered formalin (Fisher) and incubated at
25uC for 10 min with shaking (200 rpm). Bacteria were washed
five times and resuspended in PBS for an approximate
concentration of 1–3610
8 CFU/ml. Bacterial killing was con-
firmed by plating of formalin-fixed Schu S4 on chocolate II agar
plates in which no colonies were observed following extensive
incubation (data not shown). Prior to formalin fixation, an aliquot
of the bacterial suspension was removed and tested for viable CFU
by plating serial dilutions on chocolate II agar.
Construction of LVS mutants
Construction of LVS strain 1664d was described previously
[34]. The F. tularensis LVS DcapC mutant was generated using
homologous recombination with a suicide plasmid. This plasmid
contained two segments homologous to regions flanking
FTL_1415 and one third of the 59 and 39 ends of this ORF,
surrounding a chloramphenicol acetyltransferase gene (cat) under
the control of the F. tularensis groE promoter (Table 1). Linearized
plasmid was electroporated into LVS [35] and double cross-over
events were selected on cysteine heart agar with 5% defibrillated
rabbit blood containing 2.5 mg/ml chloramphenicol. Recombina-
tion was confirmed by PCR (data not shown).
To generate strain 13B47, plasmid pSD26 (a gift from Eric
Rubin and Simon Dillon) was electroporated into LVS as
previously described [36]. pSD26 is an E. coli plasmid delivery
vector (colE1,A p
R) that encodes a Himar1 transposase [37] and a
transposon containing a kanamycin resistance cassette under the
control of the F. tularensis groE promoter (Table 1). Following
recovery in trypticase soy broth supplemented with 0.1% cysteine,
bacteria were plated on cysteine heart broth with 5% defibrinated
rabbit blood containing kanamycin (5 mg/ml). Colonies that
emerged in the presence of kanamycin were isolated and screened
for lack of response to extracellular spermine [38]. The selection
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endogenous polyamine biosynthesis, dicyclohexylamine [38].
Transposon mutants that failed to grow were then tested for their
ability to stimulate cytokines [38]. Strain 13B47 elicited high
concentrations of TNF-a from human macrophages and had a
transposon insertion in FTL_0883 [38]. DNA sequencing showed
that the precise location of this transposon was in base pair 115 of
842 from the 59 end of FTL_0883. Construction of an in-frame
deletion mutant, DFTL_0883, and a cis-complement strain was
described previously [38].
Infection of macrophages and DCs with F. tularensis LVS
strains
Human monocytes were differentiated into macrophages and
DCs by in vitro culture as described previously [34]. For
generation of murine DCs, bone marrow was flushed from
femurs and tibias of C57BL/6J mice with complete DC medium
[DMEM supplemented with 10% heat-inactivated FBS, 25 mM
HEPES, 1% non-essential amino acids, 1% sodium pyruvate,
1% GlutaMAX and 0.1% 2-mercaptoethanol (all from Gibco)].
Freshly isolated cells were washed and red blood cells were lysed
with ACK Lysis Buffer (Gibco). After washing and counting,
cells were resuspended in complete DC media supplemented
with 500 U/ml GM-CSF (eBioscience) and seeded into T75
flasks or 24-well plates at a concentration of 20–30 million cells
per flask or 1610
6 cells/well, respectively. Cells were incubated
at 37uC, 5% CO2 for 5–6 days and fresh complete DC media
with 500 U/ml GM-CSF was added every 2 days. Bone marrow
DCs (BMDCs) were purified using CD11c magnetic beads
(Miltenyi Biotec) per the manufacturer’s instructions. The
resulting cells were greater than 90% CD11c
+ as assessed by
flow cytometry.
For cytokine and flow cytometry experiments, human cells were
washed and resuspended in DMEM supplemented with 1%
human serum, 25 mM HEPES, and 1% GlutaMAX. Murine
BMDCs were washed and resuspended in DMEM supplemented
with 10% FBS, 25 mM HEPES, 1% non-essential amino acids,
1% sodium pyruvate, 1% GlutaMAX and 0.1% 2-mercaptoeth-
anol (all from Gibco). DCs and macrophages were seeded into 24-
well plates (Costar) at 5610
5 cells/well and 1.5610
5 cells/well,
respectively. Infections were conducted using two different
methods with the goal of maintaining eukaryotic cell viability. A
multiplicity of infection (MOI) of 10 was used for 24-hour co-
cultures at 37uC with 5% CO2, allowing cultures to proceed
without washing. In other experiments, DCs were cultured with
bacteria at an MOI of 500 for two hours as described below,
which results in a high infection rate but with minimal effects on
cell viability [25,34]. As a positive control, macrophages and DCs
were stimulated with E. coli strain sd-4 (ATCC 11143) [39].
Supernatants were collected at various times post infection (6, 12,
24, and 48 hours) and DCs were prepared for flow cytometric
analysis.
Gentamicin protection assays were used to assess intracellular
growth [40]. Here, macrophages and DCs were seeded in
Primaria 96-well culture dishes (BD Biosciences) at a density of
5610
4 cells/well and infected with bacteria at an MOI of 500.
After two hours, cells were incubated with Hanks balanced salt
solution (Gibco) containing gentamicin (20 mg/ml) for 20 min to
kill extracellular bacteria. Cultures were then washed three
times with warm Hank’s balanced salt solution and incubated at
37uCw i t h5 %C O 2 for another 22 h with fresh culture medium.
Actual MOIs were measured by plating serial dilutions of
inocula on chocolate II agar plates. At the indicated time points
post infection, viable CFU were measured as described
previously [34,41]. Bacterialg r o w t hw a sc o m p a r e du s i n g
Student’s t-test.
For DC-T cell co-culture assays, DCs were resuspended in
complete T cell medium [DMEM supplemented with 10% heat-
inactivated FBS, 25 mM HEPES, 1% non-essential amino acids,
1% sodium pyruvate, 1% GlutaMAX and 0.1% 2-mercaptoeth-
anol (all from Gibco)] and seeded in 96-well round bottom plates
(BD Biosciences) at a density of 2610
4 cells/well. DCs were
cultured with different F. tularensis LVS strains at an MOI of 10 for
24 hours prior to co-culture with T cells (see ‘‘Human DC-CD4
+
T cell co-culture’’).
Table 1. Bacterial strains, plasmids, and primers used in this study.
Strain, plasmid, or primer Description Source or Reference
F. tularensis Strains
LVS F. tularensis subsp. holarctica live vaccine strain Karen Elkins
13B47 LVS with the Tn from pSD26 disrupting FTL_0883 in base pair 115 of 842 from the 59 end This study
1664d LVS deoB (FTL_1664) disruption mutant [25]
DcapC LVS containing cat replacing the central one third of capC (FTL_1415) This study
DFTL_0883 LVS FTL_0883 in-frame deletion mutant [38]
DFTL_0883::pJH1-FTL-0883 LVS DFTL_0883 cis-complement [38]
E. coli Strains
sd-4 Streptomycin-dependent E. coli mutant (ATCC 11143) ATCC 11143
Plasmids
pSD26 E. coli shuttle plasmid (colE1, Ap
R) encoding the C9 transposase and himar transposon (Km
R) Simon Dillon and Eric Rubin
Primers
capC-1 59–CCGCGGAAGCGACACATGGACTTTTGA–39 This study
capC-2 59–GAATTCAATATGATAATAGTTACTATAACT–39 This study
capC-3 59–ATGCATTTATATTATCCCTGGACTTAT–39 This study
capC-4 59–ACTAGTTTAGATTTTTTATTATCGTTA–39 This study
doi:10.1371/journal.pone.0031172.t001
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Surface markers on F. tularensis-infected human monocyte-
derived DCs were evaluated by flow cytometric analysis. Following
infection, DCs were removed from 24-well plates using a 2 mM
EDTA solution. Cells were washed once and resuspended in
FACS staining buffer [0.1% bovine serum albumin and 0.1%
sodium azide in PBS]. Nonspecific antibody binding was blocked
with human FcR Blocking Reagent (Miltenyi Biotec). Cells were
stained with fluorescein isothiocyanate (FITC)-conjugated anti-
CD1b (clone MT-101, AbD Serotec), phycoerythrin (PE)-conju-
gated anti-CD86 (clone IT2.2, eBioscience), PE-Cy5-conjugated
anti-CD80 (clone 2D10.4, eBioscience), and PE-Cy7-conjugated
anti-HLA-DR (clone LN3, eBioscience) at 4uC for 30 min. Isotype
control antibodies were included in each experiment to confirm
specificity of staining. After washing and fixing in 2% parafor-
maldehyde for 30 min at 4uC, cells were analyzed using a LSRII
flow cytometer (BD Biosciences) and FlowJo Software (Tree Star).
Statistically significant differences in CD80, CD86, and HLA-DR
expression by infected DCs were determined by one-way
ANOVA, followed by Bonferroni comparison of means.
Human DC-CD4
+ T cell co-culture
DC-T cell co-cultures were performed similarly to previous
studies [42,43,44]. CD4
+ T cells were purified from human
peripheral blood mononuclear cells that passed through the
Optiprep gradient by positive selection using the Dynal CD4
Positive Isolation Kit (Invitrogen) per the manufacturer’s instruc-
tions. These cells were .95% CD3
+CD4
+ T cells as assessed by
flow cytometry. Purified CD4
+ T cells were then stained with
2.5 mM CFSE for 10 min at 37uC, washed, and resuspended in
complete T cell medium. CFSE-labeled T cells from a single
donor were then added to DCs from a different donor that had
been exposed to bacteria. DC-T cell co-cultures were performed in
a 96-well round bottom plate at a ratio of 10:1 (2610
5 T cells/
2610
4 DCs/well) for a period of 5 days at 37uC with 5% CO2.
After harvesting supernatants, cells were washed once and
resuspended in FACS staining buffer, treated with human FcR
Blocking Reagent (Miltenyi Biotec), and stained with APC-
conjugated anti-CD4 (clone OKT4, eBioscience) at 4uC for
30 min. After washing and fixing in 2% paraformaldehyde for
30 min at 4uC, fluorescence was measured using a FACSCalibur
flow cytometer (BD Biosciences) and analyzed with FlowJo
Software (Tree Star). For T cell proliferation, CFSE
low cells were
measured in the CD4
+ gate. Statistically significant differences in
the percentage of proliferating T cells following co-culture with
infected DCs were determined by one-way ANOVA, followed by
Bonferroni comparison of means.
Mice
Six- to eight-week old female C57BL/6J mice were purchased
from Jackson Laboratories (Bar Harbor, ME). Mice were housed
in microisolator cages under specific pathogen-free conditions in a
biosafety level-3 animal facility.
Immunization of mice
LVS and DFTL_0883 were cultured in MH broth or TSBc as
described above. Mice were immunized subcutaneously (s.c.) or
intratracheally (i.t.). Vaccinations were performed i.t. by
oropharyngeal instillation as described previously [41]. A subset
of mice was sacrificed at 2 hours post infection, and their lungs
were homogenized and plated to confirm delivery of bacteria to
the respiratory tract. Actual administered doses were determined
by plating serial dilutions of the inocula onto chocolate II agar
plates.
Infection of mice with F. tularensis Schu S4
Schu S4 was grown in MH broth as described above. Mice were
infected i.t. with 100 CFU of Schu S4 six weeks following LVS or
DFTL_0883 vaccination. The actual dose was calculated by
plating serial dilutions of the inoculum onto chocolate II agar
plates. Following infection, mice were monitored daily for survival.
Measurements of bacterial burden in vivo
Bacterial burdens in the organs of mice vaccinated with LVS
strains were measured as previously described [38,41]. Mice were
sacrificed at the indicated time points and lungs, spleens, and livers
were removed and homogenized in 1 ml (lungs, spleens) or 2 ml
(livers) of TSBc. A portion of the organ homogenates were serially
diluted and plated onto chocolate II agar plates. Plates were
incubated at 37uCa t5 %C O 2 and individual colonies were
enumerated.
In vitro stimulation of lung cells from vaccinated mice
Six weeks following vaccination with LVS or DFTL_0883, lungs
were excised, minced, and incubated in RPMI (Gibco) supple-
mented with 12 mg type I collagenase (Gibco), 100 mg DNase I
(USB), and 3 mM CaCl2 for 30 min at 37uC with shaking
(170 rpm). The digested tissue was passed through a 40 mm cell
strainer (BD Biosciences) to generate single cell suspensions.
Erythrocytes were lysed with ACK Lysis Buffer (Gibco) and
remaining cells were washed with RPMI. Viable cells were
counted using trypan blue exclusion. Cells were resuspended in
complete RPMI [RPMI supplemented with 10% heat-inactivated
FBS, 25 mM HEPES, 1% non-essential amino acids, 1% sodium
pyruvate, 1% GlutaMAX and 0.1% 2-mercaptoethanol (all from
Gibco)] and seeded into 96-well round bottom plates at 1.5610
6
cells/well. Lung cells from naı ¨ve mice served as controls. BMDCs
were generated as described above without CD11c magnetic bead
purification. BMDCs were resuspended in complete RPMI and
added at a 1:10 ratio (1.5610
5 BMDCs/1.5610
6 lung cells) to
lung cells.
Preliminary experiments were performed with lung cells from
LVS-vaccinated mice to determine the optimal antigen concen-
tration and length of co-culture for this assay. Peak cytokine
production was detected after 48 hours of co-culture with similar
results observed at 72 hours (data not shown). Little to no cytokine
production was detected from lung cells cultured with BMDCs
and ffSchu S4 below an MOI of 10 (data not shown). As a result,
cells were incubated at 37uC with either media alone or ffSchu S4
at dose of 10 CFU per cell. After 48 hour co-culture, supernatants
were collected for analysis of cytokines and chemokines.
Cytokine and Chemokine Assays
DCs and macrophage supernatants were tested by ELISA using
commercially available kits to measure TNF-a (R&D Systems), IL-
12p40 (human, R&D Systems; mouse, eBiosciences), and IL-6
(human, R&D Systems) according to the manufacturer’s instruc-
tions. IFN-c in supernatants from human DC-CD4
+ T cell co-
cultures was also measured by ELISA (human, R&D Systems).
The limits of detection for the ELISAs were: human TNF-a –
15.6 pg/ml, human and mouse IL-12p40 – 31.2 pg/ml, human
IL-6 – 9.7 pg/ml, and human IFN-c – 15.6 pg/ml. Cytokine and
chemokine levels in lung supernatants from in vitro re-stimulation
assays were determined by ELISA (mouse IFN-c, R&D Systems;
mouse IL-17A, Biolegend) or by using the Milliplex 32-plex Mouse
APC Stimulation and Vaccine Efficacy of LVS Mutant
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(Bio-Rad Laboratories). Analyte concentrations were calculated
against the standards using Milliplex Analyst software (version 3.5;
Millipore). The limits of detection for the ELISAs were 31.2 pg/
ml for mouse IFN-c and 15.6 pg/ml for mouse IL-17A.
Statistically significant differences in cytokine production were
identified by one- or two-way ANOVA followed by Bonferroni
comparison of means.
Results
Limited inflammatory response of human DCs to LVS
We have shown previously that human macrophages have a
limited capacity to produce proinflammatory cytokines following
infection with LVS [25]. We hypothesized that human DCs would
also be hyporesponsive to LVS stimulation. To test this, human
macrophages and DCs were co-cultured with LVS, and then
supernatants were harvested and analyzed for the proinflamma-
tory cytokines TNF-a, IL-6, and IL-12p40. Similar to our findings
with macrophages (Fig. 1A), LVS elicited little to no proin-
flammatory cytokines from human DCs (Fig. 1B). Pre-treating
LVS with 100% human serum failed to enhance cytokine
production (data not shown). As a positive control, human DCs
were stimulated with E. coli [39]. E. coli-stimulated DCs produced
significantly higher levels of all cytokines measured compared to
untreated DCs or DCs cultured with LVS (Fig. 1B).
Identification of an immunostimulatory F. tularensis LVS
strain
We hypothesized that a LVS mutant inducing a stronger
proinflammatory response from APCs in vitro would be a more
effective tularemia vaccine candidate. Surveying pre-existing LVS
mutants generated in our laboratory, we tested several for their
Figure 1. F. tularensis LVS strain 13B47 stimulates human monocyte-derived DCs and macrophages to produce proinflammatory
cytokines. LVS and LVS mutants, 13B47, DcapC, and 1664d, were cultured overnight in a chemically defined media (CDM) or Mueller-Hinton (MH)
broth. The four bacterial cultures were used to inoculate macrophages (A, 1.5610
5 cells/well) and DCs (B and C, 5610
5 cells/well) at an MOI of 10. As a
positive control, DCs and macrophages were cultured with E. coli strain sd-4 (MOI=10). Supernatants were harvested after 24 hours (A–B) or at
indicated times (C), and TNF-a, IL-6, and IL-12p40 were measured by ELISA. Data are expressed as the mean 6 SEM of three individual experiments
with different donors. The level of cytokine production from each group was compared by a one (A–B) or two-way ANOVA (C), followed by the
Bonferroni comparison of means. ($$$, p,0.001 for E. coli vs. all other groups). When comparing only the DCs infected with the F. tularensis strains,
13B47 elicited higher cytokine production than the uninfected group (A–B) or LVS cultured in the same media (C). *, p,0.05; **, p,0.01;
***, p,0.001. BLD=below limits of detection of the ELISA.
doi:10.1371/journal.pone.0031172.g001
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macrophages (Table 1). Human DCs and macrophages were co-
cultured with each of the mutants in parallel with wild-type LVS,
and supernatants were analyzed for cytokines. Cytokine produc-
tion by DCs and macrophages infected with either DcapC or
1664d was similar to LVS-infected cells at 24 hours post infection
(Fig. 1A–B). In contrast, DCs and macrophages infected with the
13B47 strain produced elevated levels of all cytokines measured
(Fig. 1A–B). Similar results were observed when cytokine levels
were measured 48 hours after infection (data not shown).
Although the cytokine levels elicited by 13B47 were lower than
those produced by cells stimulated with E. coli (Fig. 1A–B), each
was readily detected. Among the LVS strains tested, therefore,
13B47 stimulated the most proinflammatory cytokines from
human APCs.
We next assessed whether the medium used to grow the bacteria
would influence stimulation of DCs. LVS grown in media
containing high levels of polyamines such as CDM stimulates
low levels of proinflammatory cytokines from macrophages
[25,27,38]. To address the effect culture conditions may have on
the DC phenotypes observed here, LVS and 13B47 were cultured
in CDM or MH broth prior to co-culture with human DCs. At
various time points post infection, supernatants were harvested
and analyzed for detection of IL-12p40. At 24 and 48 hours post
infection, greater than 10-fold higher levels of IL-12p40 were
produced by human DCs cultured with 13B47 compared to wild-
type LVS (Fig. 1C). IL-12p40 production by DCs was higher
regardless of whether 13B47 was cultured in CDM or MH broth
(Fig. 1C). This result indicated that induction of cytokine
production by 13B47 was not dependent on the growth medium
used to culture this strain.
Maturation of DCs infected with F.tularensis strain 13B47
In addition to the secretion of cytokines, DCs must undergo a
process called maturation in order to efficiently prime T cells and
initiate the adaptive immune response [45]. Among these
alterations, the expression of MHC and costimulatory molecules
increases. Since 13B47 stimulated cytokine production from
human DCs, we next evaluated whether these cells also changed
their surface phenotype in response to this mutant. The expression
of CD80, CD86, and HLA-DR was measured on DCs following
culture with either wild-type F. tularensis LVS, 13B47, DcapC,
1664d, or E. coli as a positive control for maturation. LVS elicited
little to no change in expression of maturation markers on the
surface of human DCs (Fig. 2A–C). Similar results were observed
with the LVS mutants DcapC and 1664d (Fig. 2B, C). In contrast,
the percentage of high-expressing cells and/or geometric mean
fluorescence intensity increased after culture with 13B47 for CD80
and CD86 (Fig. 2). A similar trend of heightened expression of
HLA-DR was also observed with 13B47-infected DCs (Fig. 2).
Likewise, E. coli-stimulated DCs increased expression of costimu-
latory molecules and MHC (Fig. 2). These data suggest that DCs
undergo maturation after exposure to F. tularensis strain 13B47
and, therefore, may be better suited to initiate an adaptive
immune response.
Growth of 13B47 in human macrophages and DCs
Intracellular growth is a hallmark of pathogenic Francisella
strains. Although 13B47 stimulated APCs to secrete cytokines and
upregulate costimulatory molecules, it was unclear if its intracel-
lular growth was altered. To test this, human DCs and
macrophages were infected with either wild-type LVS or strain
13B47, and lysed at various times post infection to enumerate
intracellular bacteria. 13B47 was attenuated for growth at
24 hours post infection in human macrophages (Fig. 3). Surpris-
ingly, 13B47 was still capable of replicating in human DCs (Fig. 3),
albeit with a slightly slower rate compared to wild-type LVS
(estimated generation time of 783 minutes versus 275 minutes for
wild-type). These phenotypes could not be attributed to a general
growth defect since 13B47 grew similar to wild-type LVS in
bacterial growth medium (data not shown). These data suggest
that, while the cytokine response to 13B47 is similar between
macrophages and DCs, these cells differ in their ability to control
growth of this mutant.
Enhanced activation of CD4
+ T cells by F. tularensis strain
13B47-infected DCs
Enhanced maturation of human DCs by 13B47 led us to
hypothesize the resulting DCs would stimulate T cells more
effectively. This was tested by measuring human CD4
+ T cell
proliferation and cytokine production following co-culture with
allogeneic DCs pre-treated with LVS, 13B47, or E. coli. T cell
proliferation was measured by CFSE dilution after co-culture with
infected DCs for 5 days as described previously [42,43,44]. An
increase in the percentage of proliferating CD4
+ T cells was
observed following co-culture with 13B47-infected DCs compared
to unstimulated CD4
+ T cells (Fig. 4A and B). This increased
percentage of proliferating CD4
+ T cells was comparable to the
level of proliferating T cells observed following co-culture with E.
coli-infected DCs (Fig. 4A and B). Similar rates of CD4
+ T cell
proliferation were observed after 7 days of culture with infected
DCs (data not shown). In contrast, the percentage of proliferating
CD4
+ T cells following co-culture with LVS-treated DCs was not
significantly different from the baseline level of proliferation
observed with unstimulated DCs (Fig. 4B).
T cell activation following co-culture with infected DCs was also
assessed by cytokine production. IFN-c concentrations in the
supernatants of the DC-T cell co-cultures described above showed
a similar trend to the proliferation data. CD4
+ T cells cultured
with 13B47-infected DCs produced higher levels of IFN-c
compared to those stimulated with LVS-infected DCs (Fig. 4C).
T cells stimulated with bacteria alone in the absence of DCs did
not proliferate or produce measurable levels of IFN-c (data not
shown). The proliferation and cytokine production data together
suggest DC maturation induced by 13B47 had measurable
consequences on T cells in vitro.
Evaluation of the LVS FTL_0883 deletion mutant as a
tularemia vaccine
Protection from virulent type A Francisella infection is largely
dependent on the development of robust T cell-mediated
immunity [46]. Based on the data obtained with human cells in
vitro, we hypothesized that vaccination with 13B47 would prolong
survival and improve T cell responses compared to LVS in mice
challenged with virulent Francisella. However, 13B47 is not optimal
since it contains a transposon that could be unstable. To generate
a more suitable vaccine candidate, an in-frame deletion mutant
was created in LVS, DFTL_0883, that does not incorporate an
antibiotic resistance marker [38]. Similar to human macrophages
[38], more IL-12p40 and TNF-a was produced by human DCs
cultured with DFTL_0883 than wild-type LVS (Fig. 5A–B). These
cytokine levels were similar to, or greater than, that produced by
DCs cultured with 13B47 (Fig. 5A–B). Moreover, IL-12p40 and
TNF-a levels continued to rise from 24–48 hours when DCs were
cultured with DFTL_0883 (Fig. 5B). To confirm the heightened
stimulation of macrophages and DCs was due to deletion of
FTL_0883, an in cis-complementing construct (pJH1-FTL_0883)
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mentation of DFTL_0883 with the wild-type copy of the gene
significantly reduced IL-12p40 and TNF-a production by human
macrophages [38] and DCs (Fig. 5B). Differential induction of IL-
12p40 from human DCs by FTL_0883 mutants and wild-type
LVS was also observed at a higher MOI of 500 (Fig. 5C).
Changes in CD80 and CD86 expression were also evaluated in
human DCs cultured with either wild-type LVS or FTL_0883
mutants. As demonstrated previously in Fig. 2, expression of
CD80 and CD86 was not altered on human DCs cultured with
wild-type LVS at a low MOI (Fig. 5D). Culturing of human DCs
with 13B47 or DFTL_0883, however, caused a statistically
significant increase in expression of both costimulatory molecules
on the surface (Fig. 5D). CD80 and CD86 expression were also
higher on DCs cultured with 13B47 or DFTL_0883 than on LVS-
infected DCs using a higher MOI (Fig. 5D). Lower levels of CD80
and CD86 were also measured on human DCs cultured with the
DFTL_0883 strain complemented with a wild-type copy of the
gene compared to DCs cultured with DFTL_0883 (Fig. 5D).
Deletion of FTL_0883 in LVS reduces its ability to replicate in
human and murine macrophages [38]. Additionally, the LVS
mutant containing a transposon insertion in the FTL_0883 gene,
13B47, was attenuated for growth in human macrophages and
replicated slowly in human DCs (Fig. 3). To measure DFTL_0883
replication in human DCs, DCs were infected with either wild-
type LVS, 13B47, DFTL_0883, or the complemented strain, and
lysed at various times post infection to enumerate intracellular
bacteria. DFTL_0883 replicated more slowly in human DCs than
wild-type LVS, exhibiting at least 5-fold less growth 24 hours post
infection (Fig. 5E). Similar results were observed 48 and 72 hours
post infection with up to a 20-fold difference in growth between
DFTL_0883 and LVS measured 72 hours post infection (Fig. 5E).
The growth kinetics for DFTL_0883 and 13B47 in human DCs
over the 72 hour period were indistinguishable (Fig. 5E). Com-
plementation of DFTL_0883 with a wild-type copy of the gene
restored growth of the mutant to near wild-type levels (Fig. 5E). In
summary, 13B47 and DFTL_0883 were similar with 1) reduced
growth in human DCs, 2) increased expression of CD80 and
Figure 2. Human monocyte-derived DCs mature following exposure to LVS strain 13B47. DCs were stimulated with either LVS, 13B47,
DcapC, 1664d, or E. coli for 24 hours (MOI=10). Cells were harvested and analyzed for changes in surface expression of CD86, CD80, and HLA-DR.
Cells were gated on CD1b-positive population. (A) Representative histograms for CD86, CD80, and HLA-DR expression on LVS-, 13B47-, and E. coli-
treated DCs from one experiment. Histograms for DcapC- and 1664d-infected DCs were similar to LVS (data not shown). (B) Mean percentages of DCs
with high CD86, CD80, and HLA-DR expression (6 SEM) from three individual experiments with different donors. (C) Geometric mean fluorescence
intensities (GMFI) of CD86, CD80, and HLA-DR (6 SEM) on DCs from three individual experiments with different donors. Statistically significant
differences in CD86, CD80, and HLA-DR expression by infected DCs were determined by one-way ANOVA, followed by Bonferroni comparison of
means (*, p,0.05; **, p,0.01; ***, p,0.001).
doi:10.1371/journal.pone.0031172.g002
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human DCs.
To test whether the phenotypes observed in human DCs were
species-specific, murine DCs were also tested with these LVS
strains. IL-12p40 levels were higher in supernatants from murine
DCs cultured with either 13B47 or DFTL_0883 compared to LVS
(Fig. 5F). Growth of strains with mutations in FTL_0883 was also
less than wild type in murine DCs (Fig. 5G). Similar to published
work [32], LVS replicated approximately 100-fold over 24 hours
in murine DCs (Fig. 5G). Both 13B47 and DFTL_0883 grew less
robustly in murine DCs, which was less than wild-type at 24, 48,
and 72 hours post infection (Fig. 5G). Growth of the DFTL_0883
was nearly restored to wild-type levels by the complementing
construct containing a wild-type copy of the gene (Fig. 5G). These
results showed that human and murine DCs responded similarly to
13B47 and DFTL_0883.
Having established the in vitro phenotypes of the DFTL_0883
strain, we next assessed its ability to stimulate adaptive immune
responses in vivo. C57BL/6J mice were vaccinated by either
subcutaneous (s.c.) or respiratory (i.t.) routes with LVS or
DFTL_0883. Mice were challenged six weeks later i.t. with the
type A F. tularensis strain Schu S4. Vaccination of C57BL/6J mice
with LVS prolongs survival but does not completely protect
against a secondary challenge with a type A Francisella strain
[47,48]. This experimental design allowed us to determine
whether DFTL_0883 vaccination conferred better protection than
LVS. All mice that received a sham vaccination with PBS
succumbed to the Schu S4 infection within 5 days following
challenge (Table 2). Although mice vaccinated s.c. with LVS and
DFTL_0883 survived longer than sham-vaccinated controls, they
still required euthanasia within 7 days of Schu S4 infection
(Table 2). No survival differences were observed between animals
vaccinated s.c. with LVS and DFTL_0883 (Table 2).
Vaccination by a respiratory route, however, showed statisti-
cally significant differences in protective efficacy. The median time
to death of mice vaccinated i.t. with LVS was approximately 10–
12 days following Schu S4 challenge (Table 2). This median time
to death was double the median time to death for sham-vaccinated
controls (5 days, Table 2) and was similar to previous work [47]. In
contrast, mice vaccinated with DFTL_0883 survived for a median
of 6 days (Table 2). Therefore, vaccination with DFTL_0883 by a
respiratory route provided less protection than that elicited by
wild-type LVS.
To investigate the differences in the protection elicited by the
two strains, we evaluated bacterial burdens in the lung and
peripheral organs following respiratory vaccination. LVS replicat-
ed exponentially in the lung for the first three days following i.t.
immunization (Fig. 6). The lung bacterial burden remained steady
until day 6 post immunization and then slowly began to decline up
to day 10 (Fig. 6). Dissemination to the spleen and liver occurred
at day 3 with LVS burden peaking at day 6 and being cleared by
day 10 (Fig. 6). Despite comparable doses of bacteria used in the
vaccinations, lower levels of DFTL_0883 were detected at all time
points in the lung and beginning at day 3 in peripheral organs post
immunization (Fig. 6). While clearance of LVS from the lung does
not occur until 22 days post infection [49], DFTL_0883 was
cleared more rapidly at approximately 10 days post infection
(Fig. 6). Viable DFTL_0883 were measured in the spleens and
livers of seven of eight mice by day 6, but none were detected in
these organs at day 10 (Fig. 6). Therefore, LVS achieved higher
numbers for a longer period of time in the lung and periphery
following vaccination.
We next sought an immunological explanation for the
performance of DFTL_0883 vaccination. We hypothesized wild-
type LVS induced superior T cell responses than DFTL_0883, and
measured cytokine and chemokine responses by lung cells after i.t.
vaccination. Cells were harvested from the lungs of LVS- and
DFTL_0883-vaccinated mice and were re-stimulated in vitro with
ffSchu S4. Cells from mice vaccinated with LVS produced higher
amounts of IFN-c with re-stimulation than cells from naı ¨ve mice
or those that received DFTL_0883 (Fig. 7). IFN-c production by
lung cells from mice vaccinated with DFTL_0883, however, was
not statistically significantly different than naı ¨ve controls (Fig. 7).
Increasing the vaccination dose of DFTL_0883 by three-fold failed
to improve IFN-c responses by the lung cells (data not shown).
Consistent with the IFN-c results, the IFN-c inducible chemokine
MIG was also higher in cultures from mice vaccinated with LVS
(data not shown). In contrast to IFN-c, cells from both vaccination
groups produced comparable amounts of IL-17 after re-stimula-
tion. A 2–3 fold increase in IL-17 production was observed in lung
cells from mice vaccinated with DFTL_0883 and LVS compared
to naı ¨ve controls (Fig. 7). No other statistically significant
differences were consistently detected in the other cytokines and
chemokines that were tested (data not shown). Therefore, the
protection elicited by LVS against Schu S4 challenge correlated
with IFN-c production by lung cells after re-stimulation with
antigen.
Discussion
Several studies, including this one, indicate LVS poorly
stimulates innate immune cells [24,25,27,29,30,32]. This suggests
insufficient activation of DCs could contribute to incomplete
protection engendered by LVS. In this study, we sought to
Figure 3. LVS strain 13B47 is attenuated for growth in human
macrophages and replicates slowly in DCs. DCs or macrophages
were infected in gentamicin protection assays (MOI=500) with LVS or
13B47 and lysed at the indicated times post infection. Data shown are
mean 6 SEM from three individual experiments with different donors.
Statistically significant differences in growth at 24 hours post infection
were determined by Student’s t-test (*, p,0.05).
doi:10.1371/journal.pone.0031172.g003
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better than wild-type LVS. The LVS mutants used in this study
(Table 1) were selected based on specific characteristics. All three
of these genes (FTL_1415, FTL_1664, and FTL_0883) have been
identified in negative selection screens in F. novicida and/or LVS to
be necessary for growth and/or survival in mice [50,51]. The
DcapC mutant was of interest because another LVS mutant in the
capBCA operon, DcapB, afforded protection in BALB/c mice
against challenge with the virulent Francisella strain Schu S4 [49].
Mutation of FTL_1664 in LVS resulted in diminished uptake by
human DCs [34], which may impact DC activation. Recently, our
laboratory has shown that LVS FTL_0883 mutants like 13B47
stimulate innate immune cells and are attenuated in vitro and in
vivo, making this mutant a possible vaccine candidate [38].
Strains with mutations in the FTL_0883 locus of LVS showed
promise based on in vitro results. The 13B47 and DFTL_0883
derivatives of LVS stimulated human DCs and macrophages
(Fig. 1, 2, and 5), which was associated with better stimulation of T
cells in vitro (Fig. 4). Contrary to our hypothesis, however,
improving APC stimulation in vitro with the DFTL_0883 strain
did not enhance protection in vivo. The median time to death
doubled in mice vaccinated in the respiratory tract with LVS
compared to naı ¨ve animals. In contrast, the median time to death
of mice vaccinated with DFTL_0883 was similar to naı ¨ve animals
(Table 2). Enhancing DC stimulation with DFTL_0883, therefore,
failed to establish a protective immune response.
The poor performance of DFTL_0883 as a vaccine may be due
directly to its attenuation. Mutation of the FTL_0883 locus in LVS
attenuates growth in macrophages and DCs (Fig. 3, 5E, and 5G,
and [38]). In addition, bacterial burdens in the lung and periphery
of DFTL_0883-vaccinated mice are less than in animals receiving
wild type (Fig. 6). Based on these findings, the attenuation and
accelerated clearance of DFTL_0883 in vivo may prevent a
sufficient adaptive immune response from being established.
Consistent with this model, restimulation of lung cells isolated
from DFTL_0883-vaccinated mice produced less IFN-c than mice
receiving wild type (Fig. 7). Since IFN-c is a critical mediator of
protective immunity against tularemia [48,52,53], the diminished
IFN-c response we observed following restimulation likely
contributed to the lack of protection after vaccination with
DFTL_0883.
Additional factors may also contribute to the vaccination
results seen in this study. Though the molecular function of the
protein encoded by FTL_0883 is unknown, it is possible that
protective antigens may not be expressed since spermine
responsiveness and transcription are altered after mutation of
FTL_0883 [38]. Alternatively, different cytokine profiles stimu-
lated in the host by the DFTL_0883 mutant may influence the
vaccine performance. Inflammatory signals such as IL-12 can
modulate T cell differentiation, promoting the generation of more
short-lived effector cells compared to memory precursors [54].
The higher levels of IL-12 stimulated by DFTL_0883 (Fig. 5) may
Figure 4. Enhanced proliferation and IFN-c production by CD4
+ T cells stimulated with LVS strain 13B47-infected DCs. Purified CFSE-
labeled CD4
+ T cells from a single donor were co-cultured with either E. coli-infected, F. tularensis LVS-infected, or 13B47-infected DCs from a different
donor at a ratio of 10:1 (2610
5 T cells/2610
4 DCs/well) for 5 days. (A) Representative dot plots showing loss of CFSE fluorescence versus CD4 staining
on day 5 for each group from one experiment. (B) The mean percentages of proliferating CD4
+ T cells were calculated (6 SEM) from five individual
experiments with different donors. (C) IFN-c levels were measured in day 5 supernatants by ELISA. Data are presented as the mean 6 SEM from four
individual experiments with different donors that were represented in Figure 4B. BLD=below limits of detection of the ELISA. Statistically significant
differences in mean percentages and GMFI for all groups were determined by one-way ANOVA, followed by Bonferroni comparison of means
(*, p,0.05; **, p,0.01; ***, p,0.001).
doi:10.1371/journal.pone.0031172.g004
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memory cells. Each of these possibilities is consistent with the
reduced IFN-c observed during re-stimulation of lung cells with
antigen in vitro. The mechanism(s) accounting for the poor re-
call responses observed with DFTL_0883 is currently being
investigated.
Figure 5. FTL_0883 deletion mutant, DFTL_0883, elicits maturation of DCs and is attenuated for growth similar to 13B47. Human (A–
E) and murine DCs (F–G) were cultured with either LVS, 13B47, DFTL_0883, or DFTL_0883::pJH1- FTL_0883 at an MOI of 10 (A–B, D, and F) or 500
followed by gentamicin treatment (C–E, and G). For cytokines, supernatants were harvested at 24 hours (A, C, and F) or the indicated time points (B),
and IL-12p40 and TNF-a were measured by ELISA. For flow cytometry experiments (D), DCs were harvested 24 hours post infection and GMFIs for
CD80 and CD86 were measured. For gentamicin protection assays (E, G), DCs were infected with LVS strains at an MOI of 500 and then lysed at
indicated time points to enumerate intracellular bacteria. Data are presented as the mean 6 SEM from at least two independent experiments.
Statistically significant differences between groups were determined by one (A, C, D, and F) or two-way ANOVA (B, E, and G), followed by Bonferroni
comparison of means (*, p,0.05; **, p,0.01; ***, p,0.001). BLD=below limits of detection of the ELISA.
doi:10.1371/journal.pone.0031172.g005
Table 2. Survival of immunized mice following intratracheal Schu S4 challenge
a.
Route Vaccine Vaccination Dose
Time to Death of Individual
Mice (days) Median Time to Death (days)
Control PBS N/A 5, 5, 5, 5, 5 5
Subcutaneous LVS 1610
4 6, 7, 7, 7, 7 7
DFTL_0883 1610
4 6, 6, 7, 7, 7 7
Intratracheal Experiment 1
LVS 1610
3 10,12,12, .33, .33 12
b
DFTL_0883 1610
3 5, 6, 6, 7, 7 6
Experiment 2
LVS 2610
3 9, 9, 10, 11, 12 10
b
DFTL_0883 2610
3 6, 6, 6, 7, 7 6
aMice were immunized with either LVS or DFTL_0883 at the indicated dose and then challenged with 100 CFU of Schu S4 i.t.
bSignificant difference p,0.005 by log rank test.
doi:10.1371/journal.pone.0031172.t002
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common outcomes with studies of other genetically altered
Francisella. Mutation of iglC or mglA, genes important for
intracellular growth of Francisella, or deletion of the purMCD
purine biosynthesis operon resulted in highly attenuated strains
that did not provide better protection than LVS against virulent
Francisella challenge [55,56,57]. In contrast, vaccination with a
DclpB mutant in the Schu S4 background is superior to wild-type
LVS [21]. A greater IFN-c response was measured four days after
challenge of mice vaccinated with the more successful DclpB
mutant than those vaccinated with LVS [58]. Coupled with our
results, IFN-c responses measured during restimulation could be a
useful predictor of vaccine efficacy.
Several recent studies have shown that IL-17 is also required for
control of F. tularensis growth and the generation of an effective
Th1 response following pulmonary challenge [59,60,61]. Although
the role of IL-17 in the immune response to acute F. tularensis
infection has been characterized [59,60,61], its role in vaccination
against tularemia remains to be elucidated. Paranavitana et al.
demonstrated that PBMCs from LVS-vaccinated individuals
produce high levels of IL-17 following in vitro re-stimulation [62].
Similarly, we have shown that pulmonary vaccination of mice with
LVS results in an increase in IL-17 compared to naı ¨ve controls
(Fig. 7). Production of IL-17, however, did not correlate with
vaccine efficacy since comparable levels of IL-17 were produced
by cells from mice receiving wild-type or DFTL_0883 vaccinations
(Fig. 7). Additionally, neutralization of IL-17 in mice successfully
protected by a Schu S4 DclpB vaccine did not reduce survival after
a pulmonary type A challenge despite increasing bacterial burden
[58]. Therefore, IL-17 alone is not sufficient to predict vaccine
efficacy.
Defining an optimal strategy for vaccine development remains a
significant challenge for many pathogens. Improving APC
stimulation using genetic modifications of LVS in this project
failed to improve protection against a virulent F. tularensis strain. In
addition, modeling vaccination and challenge in vitro with human
cells did not predict in vitro responses in mice. Comparison of
different vaccine strains and the protection conferred, however,
confirmed IFN-c production as a potential correlate of protection.
A similar experimental approach by Shen et al.. successfully
characterized the immune response to Francisella strains that varied
in vaccine efficacy [58]. Nevertheless, our current study and that
of Shen et al. are limited by the conditions tested (the number of
vaccine and mouse strains used), the limited number of output
variables measured (relying primarily on multiplex cytokine
measurements), and the timing of sampling (responses tested after
challenge in vitro or in vivo). This leaves open the possibility that
more comprehensive investigations could yield additional insights.
Recently, a systems-wide analysis of vaccine responses against
yellow fever has met with significant success [63,64]. In this
approach, genome-wide transcriptional studies using microarrays
provided a broader assessment of in vivo host responses to
vaccination [63]. A seminal application of these concepts to
Francisella was also recently published by DePascalis et al. [65].
Here, an in vitro lymphocyte-macrophage co-culture was used to
model the immune responses elicited by LVS vaccines of varying
efficacies [65]. Analysis of 84 immunologically-relevant genes by
real time PCR identified a list of immune mediators whose
expression pattern correlated with protection from F. tularensis
infection, including IFN-g [65]. These higher order analyses,
which integrate multi-parameter data sets of a variety of
measurements, combined with traditional testing of specific
Figure 6. DFTL_0883-vaccinated mice have reduced bacterial burdens. Mice were vaccinated i.t. (1.5610
3 CFU) with either LVS or
DFTL_0883 (n=4 mice/group/time point). At indicated time points (days 1, 3, and 6 for experiment 1; days 3, 6, and 10 for experiment 2), mice were
sacrificed and the CFU/organ was determined as described in Materials and Methods. The limits of detection for the lung, spleen, and liver are
depicted by the black dashed lines and were 100, 100, and 200 CFU, respectively. Data are presented as mean 6 SD for each individual experiment.
Statistically significant differences between groups in each experiment were determined by two-way ANOVA, followed by Bonferroni comparison of
means (*, p,0.05; ***, p,0.001).
doi:10.1371/journal.pone.0031172.g006
Figure 7. Cells from mice vaccinated with LVS produce more
IFN-c after re-stimulation. Mice were vaccinated i.t. (8610
3 CFU)
with either LVS (n=3) or DFTL_0883 (n=4). Age-matched naı ¨ve mice
(n=3) served as negative controls. Lung cells were isolated from
vaccinated and unvaccinated mice 30 days post vaccination and
incubated with formalin-fixed SchuS4 (ffSchu S4) and BMDCs. Culture
supernatants were collected 48 hours later and assessed for multiple
cytokines and chemokines using the Milliplex 32-plex Mouse Cytokine/
Chemokine Panel (Millipore) on a Bio-Plex system (Bio-Rad Laboratories,
Inc.). Baseline levels of cytokine/chemokine production were estab-
lished by the culturing of lung cells in media alone (no antigen). Data
are presented as the mean 6 SD of triplicate wells from one individual
experiment. Another experiment of similar design was performed with
a vaccination dose of 500 CFU i.t., and IL-17 and IFN-c levels were
measured by ELISA. Similar results were observed in both experiments.
Statistically significant differences in cytokine/chemokine production
were determined by a one-way ANOVA, followed by Bonferroni
comparison of means. (**, p,0.01; ***, p,0.001 for LVS v. DFTL_0883
following ffSchu S4 re-stimulation).
doi:10.1371/journal.pone.0031172.g007
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protection and biological response modifiers that may be exploited
during acute infection and vaccination.
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